期刊文献+

替吉奥治疗老年胃癌患者的临床疗效 被引量:3

Clinical curative effect of S1 capsule for treatment of elderly patients with gastric cancer
原文传递
导出
摘要 目的探讨替吉奥治疗老年胃癌患者的疗效及不良反应。方法选取2008年7月至2012年5月收治的年龄≥60岁的老年胃癌患者126例,随机分为观察组(替吉奥治疗组,63例)和对照组(63例)。观察组患者采用替吉奥胶囊治疗,对照组采用奥沙利铂联合亚叶酸钙和氟尿嘧啶方案治疗。治疗结束后,对两组患者的有效率、不良反应和治疗满意度等分别进行统计分析。结果观察组患者的总有效率为88.9%,对照组患者的总有效率为71.4%,两组差异有统计学意义(P<0.05)。患者主要的不良反应为肝功能损伤、骨髓抑制和胃肠道反应,观察组患者出现III~IV级不良反应者8例(12.7%),对照组为15例(23.8%),两组差异有统计学意义(P<0.05)。对患者的治疗满意度统计显示,观察组患者的总满意度为61.9%,对照组为55.6%,两组差异无统计学意义(P>0.05)。结论替吉奥治疗老年胃癌患者疗效显著,不良反应较低,患者满意度较高。 Objective Through the use of S1 capsule to the treatment of elderly patients with gastric cancer,the curative effect and adverse reaction were observed.Methods From July 2008 to May 2012,126 elderly patients(age≥60 years)with gastric carcinoma in our hospital were selected and randomly divided into two groups,the observation group(63 cases)and control group(63 cases).The patients of observation group with S1 capsule treatment,the patients of control group using oxaliplatin leucovorin and 5-fluorouracil regimen in treatment of.After the end of treatment,two groups of patients with treatment efficiency,adverse reaction,patient treatment satisfaction were analyzed.Results observation group patients with a total efficiency of 88.9%,compared to the control group in a total efficiency of 71.4%,there are statistical significance(P0.05).The main adverse reactions in liver function injury,bone marrow suppression,gastrointestinal reactions in three aspects,observation group patients with III-IV toxicity and side effects of 8 cases(12.7%),while the control group of 15 cases(23.8%),there are statistical significance(P0.05).Observation group patients with a total treatment satisfaction of 61.9%,and the control group was 55.6%,there is no statistical significance.Conclusions Application of S1 capsule to the treatment of elderly patients with gastric cancer curative effect remarkable,produce toxic side effect is low,patient satisfaction is high.
出处 《中国肿瘤临床与康复》 2013年第1期24-26,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 胃肿瘤 老年人 替吉奥 不良反应 Gastric neoplasms Aged S1 capsule Adverse reaction
  • 相关文献

参考文献5

二级参考文献36

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Koizumi W,Narahata H,Hara T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.
  • 3Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phase Ⅱ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
  • 4Jemal A, Segel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2009, 59(4): 225.
  • 5Lichtman SM, Balducci L, Aapro M. Geriatric oncology: a field coming of age[J]. J Clin (hlcol, 2007, 25(14) : 1821.
  • 6Tsujimoto S, Fujimoto K, Okajima E, et al. 5 - Fluorouracil incorporated into the tiasue RNA of human and rat bladder carcinoma after administration of 1 - (2 - tetrahydrofuryl) - 5- fluorouracil combined with uracil[J]. Int J Clin Oncol, 2008, 13(2): 138.
  • 7Fukushima M. [ Antitumor activity and function of S- 1, a new oral tegafur - based formulation ] [ J ]. Gan To Kagaku Ryoho, 2006, 33 (Suppl 1): 19.
  • 8Maehara Y. S 1 in gastric cancer: a comprehensive review [J]. Gastric Cancer, 2003, 6 (Suppl 1): 2.
  • 9Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase Ⅱ study of S - 1, a novel oral derivative of 5 - fluorouracil, in advanced gastric cancer. For the S- 1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000, 58(3) : 191.
  • 10Lee J L, Kang Y K, Kang H J, et al. A randomised multi- centre phase Ⅱ trial of capecitahine vs S- 1 as first- line treatment in elderly patients with metastatic or recurrent un- resectable gastric cancer [ J ]. Br J Cancer, 2008, 99 (4) : 584.

共引文献289

同被引文献26

  • 1任会学,毛进隆.昔布类药物的心血管副作用研究综述[J].化工中间体,2006,2(1):1-5. 被引量:2
  • 2朱风尚,陈锡美,王毅军,张霞,冯久贤.特异性环氧合酶抑制剂和抗癌药联用对胃癌细胞增殖的影响[J].中华肿瘤杂志,2007,29(3):186-188. 被引量:15
  • 3Shirasaka T. Development history and concept of an oral anticancer agent S-1 ( TS-1 ) : its clinical usefulness and future vistas [ J]. Jpn J Clin Oncol,2009,39( 1 ) :2-15.
  • 4Shirasaka T,Tsukuda M, Inuyama Y, et al. New oral anticancer drug, 1322 TS-1 ( S-1 ) : from bench to clinic [ J ]. Can To Kagaku Ryoho, 2001,28 ( 6 ) : 855 -864.
  • 5Chen Z, Liu M, Liu X,et al. COX-2 regulates Ecadherin expres- sion through the NF-kB/Snail signaling pathway in gastric cancer [ J]. Int J Mol Med,2013,32 ( 1 ) :93-100.
  • 6Okano H, Shinohara H, Miyamoto A,et al. Concomitant overexpres- sion of cyclooxygenase-2 in HER-2-positive on Smad4-redueed hu- man gastric carcinomas is associated with a poor patient outcome [ J 1. Clln Cancer Res, 2004,10 ( 20 ) : 6938-6945.
  • 7Da M X, Wu X T, Wang J, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lym- phangiogenesis and lymphatic invasion in human gastric cancer [ J ]. Arch Med Res, 2008,39 ( 1 ) :92 -99.
  • 8Bunis H A 3rd, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [ J]. J Clin Oneol, 1997,15 (6) :2403-2413.
  • 9Bang J,Kim Y W,Yang H K,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) :a phase 3 open-label, randomised controlled trial [ J ]. Lancet,2012, 379(9813) :315-321.
  • 10Wu C Y, Wu M S, Kuo K N, et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-in//ammatory drugs in Helicobacter pylori-infected patients [ J ]. J Clin Oncol, 2010,28(18) :2952-2957.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部